XOVR price is the search query that surfaces right after someone watches Matt Milner’s “The Next Elon Musk” presentation and hears him spell out the ticker letter by letter, promising around $50 a share. It is a real ticker, a real ETF, and it really does trade in that price range. But the price alone does not tell you what you are buying, and that is where the honest explanation has to start. Here is what XOVR is, what its price reflects, and what it actually gives you exposure to.
What the Ticker Is
XOVR is the ERShares Private-Public Crossover ETF, converted from the ENTR Entrepreneurs ETF in August 2024. The fund’s design is to hold a blend of public and private companies, which is what the “crossover” label means. Among its private holdings are Anduril and SpaceX, plus a broader set of roughly 30 private names, alongside a larger allocation to public companies. It is one of the few ways a retail investor can gain indirect exposure to private-tech names without accreditation, which is exactly why Milner hands it out for free.
What the Price Reflects
At around $50 a share, XOVR trades in the range Milner cites in the video, and that price is simply the fund’s net asset value divided by its share count, the same mechanics as any ETF. It is an entry point, not a signal. The more important number is the composition of the fund, because the price you pay buys a diversified basket, and the share of Anduril inside that basket is small. Tracking the price tells you where the fund trades; it does not tell you how much of any single company you own.
The Anduril Sliver
The honest detail, which Milner states himself, is that Anduril is not in XOVR’s top 10 holdings, and private companies as a whole make up only about 15% of the fund. So the “backdoor into Anduril” is a diluted one: your dollars buy a diversified crossover fund with a modest private sleeve, and Anduril is one name within that sleeve. The presentation is candid about this, even warning that the fund could sell its private shares and shrink the sliver further. That candor is uncommon in this genre, and it matters.
The Pivot to the Paid Picks
That dilution is also the engine of the pitch. After giving away XOVR, Milner argues that the concentrated 10x returns will come from the smaller suppliers feeding Anduril’s production lines, not from a diversified ETF. Those supplier names sit behind a $299 trial of the Grey Swan Investment Fraternity. XOVR, in other words, is the free proof that the presentation is grounded in something real, while the paid report carries the actual thesis.
For the full teardown of the presentation and its claims, read our complete Next Elon review. For the broader pre-IPO theme, see our OXF AI IPO review, and for the defense-tech angle, see our AI defense stocks piece.
How the Price Compares to the Pitch
The presentation’s price claim is one of its easiest to verify, and it holds up. Milner says you can buy XOVR for around $50 a share as he is recording, and the fund has traded in that neighborhood, which makes this one of the rare teasers where the free giveaway checks out on the exact detail it leads with. The reason that matters is that it signals the rest of the pitch is grounded in real securities rather than invented tickers, a bar that surprisingly many promos in this genre fail. The price, though, is only the entry point. What you get for your $50 is a diversified crossover fund, and the share of Anduril inside it is small, which is the part the price alone obscures. The honest summary is that the XOVR price is real and the ticker is real, and the presentation earns credibility on that front, while the substance of the Anduril bet lives elsewhere, in the supplier names behind the paywall. That division, a real free ticker up front and a paid thesis behind it, is the clearest way to understand what the presentation is actually doing. We walk through the specifics in our XOVR ETF Price: Valuing the Pre-IPO Crossover Fund piece.
Our Take
The XOVR price is real, the ticker is real, and it genuinely trades near $50, which makes this one of the more verifiable free giveaways we have reviewed. The honest caveat is that the price buys a diversified crossover fund, not a concentrated Anduril stake, and the presentation is upfront about that limit. Whether a diluted private-tech sleeve is what you want, or whether you would rather bet on the concentrated supplier names behind the paywall, is the decision the pitch leaves with you.
Ready to see the research? Click here to access Matt Milner’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.